Advertisement
Screener

MEREO BIOPHARMA GROUP PLC (MREO) Net Change in Cash

2.8 / 5 stars · 68/120 Roast Me

MEREO BIOPHARMA GROUP PLC Net Change in Cash

MEREO BIOPHARMA GROUP PLC (MREO) reported Net Change in Cash of $12.38 million for the 12-month period ending 2024-12-31, per its 10-K filed 2025-03-26.

Financial Statements › Cash Flow › Change in Cash

us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect · last filed 2025-03-26

  • MEREO BIOPHARMA GROUP PLC cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), including exchange rate effect for fiscal 2024 was $12.38M.
  • MEREO BIOPHARMA GROUP PLC cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), including exchange rate effect for fiscal 2023 was -$10.76M.
Period endCash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect 9 monthCash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect 12 month
2024-12-31$12.38M
10-K · filed 2025-03-26
2024-09-30$23.10M
10-Q · filed 2024-11-12
2023-12-31-$10.76M
10-K · filed 2025-03-26
2023-09-30-$5.65M
10-Q · filed 2024-11-12

Similar stocks

Stock NameCountryMarket CapPE Ratio
Greenwich LifeSciences, Inc. (GLSI)United States$0.267B-15.02
Sagimet Biosciences Inc. (SGMT)United States$0.279B
Akebia Therapeutics, Inc. (AKBA)United States$0.255B-10.35
Upstream Bio, Inc. (UPB)United States$0.284B-2.42
Perspective Therapeutics, Inc. (CATX)United States$0.284B-3.34
Contineum Therapeutics, Inc. (CTNM)United States$0.289B-4.40
Fulcrum Therapeutics, Inc. (FULC)United States$0.289B-3.28
Lyell Immunopharma, Inc. (LYEL)United States$0.248B-1.32
Pyxis Oncology, Inc. (PYXS)United States$0.244B
ROCKET PHARMACEUTICALS, INC. (RCKT)United States$0.296B-21.78